Cardiovascular Considerations for Methylphenidate Treatment

Contraindications and Precautions

The American College of Cardiology recommends avoiding methylphenidate in patients with uncontrolled hypertension, underlying coronary artery disease, and serious cardiac arrhythmias or tachyarrhythmias 1
Patients with pre-existing hypertension should have their blood pressure controlled to target (<140/90 mmHg minimum, ideally <130/80 mmHg) before initiating methylphenidate, and their antihypertensive regimen should be reviewed for adequacy 2, 3

The American College of Cardiology recommends systematic cardiovascular surveillance, including monitoring blood pressure and pulse at every visit, and checking for signs of hypertension and tachycardia regularly 2
If blood pressure rises during methylphenidate treatment, the dosage of antihypertensive medications may need to be adjusted, and consideration should be given to reducing the dose of methylphenidate or discontinuing it if blood pressure cannot be adequately controlled 2
The American College of Cardiology guidelines classify amphetamines, including methylphenidate, as substances that may impair blood pressure control, and recommend discontinuation or dose reduction when feasible 2

The American College of Cardiology recommends considering behavioral therapies for ADHD as alternatives to stimulants when cardiovascular risk is a concern, particularly for patients with poorly controlled hypertension, history of cardiovascular events, or multiple cardiovascular risk factors 2

The American Heart Association and American College of Cardiology guidelines emphasize the importance of not assuming "normal" baseline blood pressure is sufficient, and not relying on single blood pressure measurements, but rather obtaining multiple readings to establish a true baseline 2, 3
Home blood pressure monitoring or ambulatory monitoring should be considered if office readings are elevated, to account for white coat hypertension 4